Trastuzumab deruxtecan, a HER2-targeting ADC with a cleavable tetra-peptide-based linker and a topoisomerase-1 (TOP1)-inhibitor payload has important antitumour activity against advanced HER2-positive breast and gastric cancer (27,28). Here, ERBB2 is linked to gastric cancer.